Skip to Main Content

Joachim Baehring, MD

Professor of Neurology and of Neurosurgery; Associate Chief, Neurology; Director, Neuro-Oncology Fellowship Program, Neurology; Vice Chair, Clinical Affairs, Neurology

Contact Information

Joachim Baehring, MD

Research Summary

The primary foci of Dr. Baehring's laboratory work are primary brain tumors and neurological complications of cancer.

Dr. Baehring is involved in clinical and translational research at Yale University School of Medicine. He is an investigator on numerous therapeutic trials for patients with glioblastoma, lymphoma, and other brain tumors. Other research interests include the molecular pathogenesis and development of molecular markers for primary CNS lymphoma.

Specialized Terms: Molecular markers of cancer; Nervous system lymphoma

Research Interests

Brain Neoplasms; Lymphoma; Medical Oncology; Neurology; Neurosurgery

Clinical Trials

ConditionsStudy Title
Brain and Nervous SystemA Phase 1 Trial to Evaluate the Safety and Tolerability of Fb-PMT in Patients With Recurrent Glioblastoma
Brain and Nervous SystemPhase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas With SMO/ AKT/ NF2/CDK Pathway Mutations
Brain and Nervous SystemA Multi-Center Phase 0/I Trial of Anti-TIGIT Antibody AB154 in Combination With Anti-PD-1 Antibody AB122 for Recurrent Glioblastoma
Brain and Nervous SystemGBM AGILE: Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent GBM
Brain and Nervous SystemGenomically-Guided Treatment Trial in Brain Metastases
Brain and Nervous SystemPhase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas
Brain and Nervous SystemPhase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma
Brain and Nervous SystemPhase III Intergroup Study of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma
Brain and Nervous SystemAn Open-label Phase II Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Tirabrutinib in Patients With Primary Central Nervous System Lymphoma (PCNSL)
Brain and Nervous SystemA Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations (FIGHT-209)